Skip to main content

Advertisement

SpringerLink
Log in

Contemporary Understandings of Cardiovascular Disease After Cancer Radiotherapy: a Focus on Ischemic Heart Disease

  • Management of Acute Coronary Syndromes (H Jneid, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Radiation-induced cardiovascular disease, including coronary artery disease, is a well-known sequela of radiation therapy and represents a significant source of morbidity and mortality for cancer survivors. This review examines current literature and guidelines to care for this growing population of cancer survivors.

Recent Findings

The development of radiation-induced ischemic heart disease following radiation can lead even to early cardiotoxicities, inclusive of coronary artery disease, which limit cancer treatment outcomes. These coronary lesions tend to be diffuse, complex, and proximal. Early detection with multimodality imaging and targeted intervention is required to minimize these risks.

Summary

Early awareness, detection, and management of radiation-induced cardiovascular disease are paramount as cancer survivorship continues to grow.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.

    Article  PubMed  Google Scholar 

  2. Shapiro CL. Cancer survivorship. N Engl J Med. 2018;379(25):2438–50. https://doi.org/10.1056/NEJMra1712502.

    Article  PubMed  Google Scholar 

  3. Strongman H, Gadd S, Matthews A, Mansfield KE, Stanway S, Lyon AR, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019;394(10203):1041–54. https://doi.org/10.1016/S0140-6736(19)31674-5.

  4. Cuomo JR, Javaheri SP, Sharma GK, Kapoor D, Berman AE, Weintraub NL. How to prevent and manage radiation-induced coronary artery disease. Heart. 2018;104(20):1647–53. https://doi.org/10.1136/heartjnl-2017-312123.

    Article  PubMed  Google Scholar 

  5. van Rosendael AR, Daniels LA, Dimitriu-Leen AC, Smit JM, van Rosendael PJ, Schalij MJ, et al. Different manifestation of irradiation induced coronary artery disease detected with coronary computed tomography compared with matched non-irradiated controls. Radiother Oncol. 2017;125(1):55–61. https://doi.org/10.1016/j.radonc.2017.09.008.

    Article  PubMed  Google Scholar 

  6. Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, et al. Cardiovascular disease risk in a large, population-based cohort of breast cancer survivors. Int J Radiat Oncol Biol Phys. 2016;94(5):1061–72. https://doi.org/10.1016/j.ijrobp.2015.11.040.

    Article  PubMed  Google Scholar 

  7. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98. https://doi.org/10.1056/NEJMoa1209825.

    Article  CAS  PubMed  Google Scholar 

  8. McGale P, Darby SC, Hall P, Adolfsson J, Bengtsson NO, Bennet AM, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol. 2011;100(2):167–75. https://doi.org/10.1016/j.radonc.2011.06.016.

  9. van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of hodgkin lymphoma. J Clin Oncol. 2016;34(3):235–43. https://doi.org/10.1200/JCO.2015.63.4444.

    Article  CAS  PubMed  Google Scholar 

  10. Desai MY, Windecker S, Lancellotti P, Bax JJ, Griffin BP, Cahlon O, et al. Prevention, diagnosis, and management of radiation-associated cardiac disease: JACC scientific expert panel. J Am Coll Cardiol. 2019;74(7):905–27. https://doi.org/10.1016/j.jacc.2019.07.006.

  11. Niska JR, Thorpe CS, Allen SM, Daniels TB, Rule WG, Schild SE, et al. Radiation and the heart: systematic review of dosimetry and cardiac endpoints. Expert Rev Cardiovasc Ther. 2018;16(12):931–50.

  12. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99. https://doi.org/10.1016/S1470-2045(14)71207-0.

  13. Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, et al. Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2020;38(7):706–14. https://doi.org/10.1200/JCO.19.01162.

  14. van den Bogaard VA, Ta BD, van der Schaaf A, Bouma AB, Middag AM, Bantema-Joppe EJ, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol. 2017;35(11):1171–8. https://doi.org/10.1200/JCO.2016.69.8480.

  15. Radiation Quantities and Units. U.S. Food and Drug Administration FDA.org. 2017. https://www.fda.gov/radiation-emitting-products/medical-x-ray-imaging/radiation-quantities-and-units. Accessed 7/13 2020.

  16. Radiology ACo. Radiation Dose to Adults From Common Imaging Examinations.

  17. Smith-Bindman R, Lipson J, Marcus R, Kim KP, Mahesh M, Gould R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009;169(22):2078–86. https://doi.org/10.1001/archinternmed.2009.427.

  18. Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European association of cardiovascular imaging and the American society of echocardiography. Eur Heart J Cardiovasc Imaging. 2013;14(8):721–40. https://doi.org/10.1093/ehjci/jet123.

  19. Kupeli S, Hazirolan T, Varan A, Akata D, Alehan D, Hayran M, et al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood hodgkin’s lymphoma. J Clin Oncol. 2010;28(6):1025–30. https://doi.org/10.1200/JCO.2009.25.2627.

    Article  PubMed  Google Scholar 

  20. Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128(17):1927–95. https://doi.org/10.1161/CIR.0b013e3182a88099.

  21. Guha A, Dey AK, Jneid H, Addison D. Acute coronary syndromes in cancer patients. Eur Heart J. 2019;40(19):1487–90. https://doi.org/10.1093/eurheartj/ehz267.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Addison D, Seidelmann SB, Janjua SA, Emami H, Staziaki PV, Hallett TR, et al. Human papillomavirus status and the risk of cerebrovascular events following radiation therapy for head and neck cancer. J Am Heart Assoc. 2017;6(9). https://doi.org/10.1161/JAHA.117.006453.

  23. Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, et al. SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of India, and sociedad Latino Americana de Cardiologia intervencionista). Catheter Cardiovasc Interv. 2016;87(5):E202–23. https://doi.org/10.1002/ccd.26379.

  24. van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, et al. Cardiovascular disease after hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007–17.

    Article  PubMed  Google Scholar 

  25. Desai MY, Jellis CL, Kotecha R, Johnston DR, Griffin BP. Radiation-associated cardiac disease: a practical approach to diagnosis and management. J Am Coll Cardiol Img. 2018;11(8):1132–49. https://doi.org/10.1016/j.jcmg.2018.04.028.

    Article  Google Scholar 

  26. Mancuso L, Mancuso A, Scordato F, Pieri M, Valerio E. Malignancy and radiation-induced cardiotoxicity. Cardiovasc Hematol Disord Drug Targets. 2011;11(2):102–8.

    Article  CAS  PubMed  Google Scholar 

  27. Altena R, Perik PJ, Van Veldhuisen DJ, De Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10(4):391–9.

    Article  CAS  PubMed  Google Scholar 

  28. Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017;35(15):1641–9.

  29. Atkins KM, Rawal B, Chaunzwa TL, Lamba N, Bitterman DS, Williams CL, et al. Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer. J Am Coll Cardiol. 2019;73(23):2976–87. https://doi.org/10.1016/j.jacc.2019.03.500.

  30. Dess RT, Sun Y, Matuszak MM, Sun G, Soni PD, Bazzi L et al. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol. 2017;35(13):1395–402.

  31. Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y, et al. Cardiac toxicity after radiotherapy for stage III non–small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol. 2017;35(13):1387–94.

  32. Konski A, Li T, Christensen M, Cheng JD, Yu JQ, Crawford K, et al. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol. 2012;104(1):72–7. https://doi.org/10.1016/j.radonc.2012.04.016.

  33. Little MP, Kleinerman RA, Stovall M, Smith SA, Mabuchi K. Analysis of dose response for circulatory disease after radiotherapy for benign disease. International Journal of Radiation Oncology, Biology, Physics. 2012;84(5):1101–9.

  34. Tait LM, Meyer JE, McSpadden E, Cheng JD, Baciewicz FA, Meropol NJ, et al. Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinoma. Pract Radiat Oncol. 2013;3(4):e149–e55.

  35. Maraldo M, Brodin NP, Aznar MC, Vogelius I, Munck af Rosenschöld P, Petersen PM, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013;24(8):2113–8.

  36. Hahn E, Jiang H, Ng A, Bashir S, Ahmed S, Tsang R, et al. Late cardiac toxicity after mediastinal radiation therapy for hodgkin lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction. Int J Radiat Oncol Biol Phys. 2017;98(5):1116–23. https://doi.org/10.1016/j.ijrobp.2017.03.026.

  37. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016;134(10):e123–55. https://doi.org/10.1161/CIR.0000000000000404.

    Article  PubMed  Google Scholar 

  38. Ebctcg, McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35. https://doi.org/10.1016/S0140-6736(14)60488-8.

  39. Taylor CW, Povall JM, McGale P, Nisbet A, Dodwell D, Smith JT, et al. Cardiac dose from tangential breast cancer radiotherapy in the year 2006. Int J Radiat Oncol Biol Phys. 2008;72(2):501–7. https://doi.org/10.1016/j.ijrobp.2007.12.058.

  40. Ares C, Khan S, Macartain AM, Heuberger J, Goitein G, Gruber G, et al. Postoperative proton radiotherapy for localized and locoregional breast cancer: potential for clinically relevant improvements? Int J Radiat Oncol Biol Phys. 2010;76(3):685–97. https://doi.org/10.1016/j.ijrobp.2009.02.062.

  41. Aznar MC, Korreman SS, Pedersen AN, Persson GF, Josipovic M, Specht L. Evaluation of dose to cardiac structures during breast irradiation. Br J Radiol. 2011;84(1004):743–6. https://doi.org/10.1259/bjr/12497075.

  42. Gulyban A, Kovacs P, Sebestyen Z, Farkas R, Csere T, Karacsonyi G, et al. Multisegmented tangential breast fields: a rational way to treat breast cancer. Strahlenther Onkol. 2008;184(5):262–9. https://doi.org/10.1007/s00066-008-1770-1.

  43. Jagsi R, Moran J, Marsh R, Masi K, Griffith KA, Pierce LJ. Evaluation of four techniques using intensity-modulated radiation therapy for comprehensive locoregional irradiation of breast cancer. Int J Radiat Oncol Biol Phys. 2010;78(5):1594–603. https://doi.org/10.1016/j.ijrobp.2010.04.072.

  44. Schubert LK, Gondi V, Sengbusch E, Westerly DC, Soisson ET, Paliwal BR, et al. Dosimetric comparison of left-sided whole breast irradiation with 3DCRT, forward-planned IMRT, inverse-planned IMRT, helical tomotherapy, and topotherapy. Radiother Oncol. 2011;100(2):241–6. https://doi.org/10.1016/j.radonc.2011.01.004.

  45. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–50. https://doi.org/10.1056/NEJMoa1809697.

  46. Bonsu J, Charles L, Guha A, Awan F, Woyach J, Yildiz V, et al. Representation of patients with cardiovascular disease in pivotal cancer clinical trials. Circulation. 2019;139(22):2594–6. https://doi.org/10.1161/CIRCULATIONAHA.118.039180.

  47. Bonsu JM, Guha A, Charles L, Yildiz VO, Wei L, Baker B, et al. Reporting of cardiovascular events in clinical trials supporting FDA approval of contemporary cancer therapies. J Am Coll Cardiol. 2020;75(6):620–8. https://doi.org/10.1016/j.jacc.2019.11.059.

  48. Arnold M, Laversanne M, Brown LM, Devesa SS, Bray F. Predicting the future burden of esophageal cancer by histological subtype: international trends in incidence up to 2030. Am J Gastroenterol. 2017;112(8):1247–55. https://doi.org/10.1038/ajg.2017.155.

  49. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337(3):161–7. https://doi.org/10.1056/NEJM199707173370304.

  50. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84. https://doi.org/10.1056/NEJMoa1112088.

  51. Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8. https://doi.org/10.1016/S1470-2045(15)00040-6.

  52. Busweiler LA, Wijnhoven BP, van Berge Henegouwen MI, Henneman D, van Grieken NC, Wouters MW, et al. Early outcomes from the Dutch upper gastrointestinal cancer audit. Br J Surg. 2016;103(13):1855–63. https://doi.org/10.1002/bjs.10303.

    Article  CAS  PubMed  Google Scholar 

  53. Kassis ES, Kosinski AS, Ross P Jr, Koppes KE, Donahue JM, Daniel VC. Predictors of anastomotic leak after esophagectomy: an analysis of the society of thoracic surgeons general thoracic database. Ann Thorac Surg. 2013;96(6):1919–26. https://doi.org/10.1016/j.athoracsur.2013.07.119.

    Article  PubMed  Google Scholar 

  54. van Leeuwen FE, Ng AK. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program. 2016;2016(1):323–30.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008;70(3):707–14. https://doi.org/10.1016/j.ijrobp.2007.10.056.

  56. Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, et al. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. J Clin Oncol. 2020;38(14):1569–79. https://doi.org/10.1200/JCO.19.02503

  57. Andersson A, Näslund U, Tavelin B, Enblad G, Gustavsson A, Malmer B. Long-term risk of cardiovascular disease in hodgkin lymphoma survivors—retrospective cohort analyses and a concept for prospective intervention. Int J Cancer. 2009;124(8):1914–7.

  58. Bilora F, Pietrogrande F, Petrobelli F, Polato G, Pomerri F, Muzzio PC. Is radiation a risk factor for atherosclerosis? An echo-color Doppler study on Hodgkin and non-Hodgkin patients. Tumori. 2006;92(4):295–8.

  59. Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, LaCasce A, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117(2):412–8.

  60. Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49(8):1486–93.

  61. Rademaker J, Schöder H, Ariaratnam NS, Strauss HW, Yahalom J, Steingart R, et al. Coronary artery disease after radiation therapy for Hodgkin’s lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients. Am J Roentgenol. 2008;191(1):32–7.

  62. Chen MH, Blackington LH, Zhou J, Chu TF, Gauvreau K, Marcus KJ, et al. Blood pressure is associated with occult cardiovascular disease in prospectively studied Hodgkin lymphoma survivors after chest radiation. Leuk Lymphoma. 2014;55(11):2477–83.

  63. Iliescu C, Durand JB, Kroll M. Cardiovascular interventions in thrombocytopenic cancer patients. Tex Heart Inst J. 2011;38(3):259–60.

  64. Schandl A, Lagergren J, Johar A, Lagergren P. Health-related quality of life 10 years after oesophageal cancer surgery. Eur J Cancer. 2016;69:43–50. https://doi.org/10.1016/j.ejca.2016.09.032.

  65. Daniels LA, Krol AD, de Graaf MA, Scholte AJ, Van’t Veer MB, Putter H, et al. Screening for coronary artery disease after mediastinal irradiation in hodgkin lymphoma survivors: phase II study of indication and acceptancedagger. Ann Oncol. 2014;25(6):1198–203. https://doi.org/10.1093/annonc/mdu130.

  66. D’Errico MP, Grimaldi L, Petruzzelli MF, Gianicolo EA, Tramacere F, Monetti A, et al. N-terminal pro-b–type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):e239–e46.

  67. Skyttä T, Tuohinen S, Boman E, Virtanen V, Raatikainen P, Kellokumpu-Lehtinen P-L. Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy. Radiat Oncol. 2015;10(1):141.

  68. Ma CX, Zhao XK, Li YD. New therapeutic insights into radiation-induced myocardial fibrosis. Ther Adv Chronic Dis. 2019;10:2040622319868383. https://doi.org/10.1177/2040622319868383.

  69. Tjessem KH, Bosse G, Fossa K, Reinertsen KV, Fossa SD, Johansen S, et al. Coronary calcium score in 12-year breast cancer survivors after adjuvant radiotherapy with low to moderate heart exposure - relationship to cardiac radiation dose and cardiovascular risk factors. Radiother Oncol. 2015;114(3):328–34. https://doi.org/10.1016/j.radonc.2015.01.006.

  70. Zagar TM, Cardinale DM, Marks LB. Breast cancer therapy-associated cardiovascular disease. Nat Rev Clin Oncol. 2016;13(3):172–84. https://doi.org/10.1038/nrclinonc.2015.171.

  71. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20. https://doi.org/10.1016/j.jacc.2009.03.095.

  72. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–90. https://doi.org/10.1016/j.annonc.2019.10.023.

  73. Khan HA, Alhomida AS. A review of the logistic role of l-carnitine in the management of radiation toxicity and radiotherapy side effects. J Appl Toxicol. 2011;31(8):707–13.

  74. Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 2003;29(6):501–13.

  75. Nguyen NP, Krafft SP, Vinh-Hung V, Vos P, Almeida F, Jang S, et al. Feasibility of tomotherapy to reduce normal lung and cardiac toxicity for distal esophageal cancer compared to three-dimensional radiotherapy. Radiother Oncol. 2011;101(3):438–42.

  76. Hayden AJ, Rains M, Tiver K. Deep inspiration breath hold technique reduces heart dose from radiotherapy for left-sided breast cancer. J Med Imaging Radiat Oncol. 2012;56(4):464–72. https://doi.org/10.1111/j.1754-9485.2012.02405.x.

  77. Rochet N, Drake JI, Harrington K, Wolfgang JA, Napolitano B, Sadek BT, et al. Deep inspiration breath-hold technique in left-sided breast cancer radiation therapy: evaluating cardiac contact distance as a predictor of cardiac exposure for patient selection. Pract Radiat Oncol. 2015;5(3):e127–34. https://doi.org/10.1016/j.prro.2014.08.003.

  78. Krengli M, Masini L, Caltavuturo T, Pisani C, Apicella G, Negri E, et al. Prone versus supine position for adjuvant breast radiotherapy: a prospective study in patients with pendulous breasts. Radiat Oncol. 2013;8:232. https://doi.org/10.1186/1748-717X-8-232.

  79. Lymberis SC, deWyngaert JK, Parhar P, Chhabra AM, Fenton-Kerimian M, Chang J, et al. Prospective assessment of optimal individual position (prone versus supine) for breast radiotherapy: volumetric and dosimetric correlations in 100 patients. Int J Radiat Oncol Biol Phys. 2012;84(4):902–9. https://doi.org/10.1016/j.ijrobp.2012.01.040.

  80. Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment. J Clin Oncol. 2012;30(30):3657–64. https://doi.org/10.1200/JCO.2012.45.2938.

  81. Addison D, Lawler PR, Emami H, Janjua SA, Staziaki PV, Hallett TR, et al. Incidental statin use and the risk of stroke or transient ischemic attack after radiotherapy for head and neck cancer. J Stroke. 2018;20(1):71–9. https://doi.org/10.5853/jos.2017.01802.

  82. Boulet J, Pena J, Hulten EA, Neilan TG, Dragomir A, Freeman C, et al. Statin use and risk of vascular events among cancer patients after radiotherapy to the thorax, head, and neck. J Am Heart Assoc. 2019;8(13):e005996. https://doi.org/10.1161/JAHA.117.005996.

  83. Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014;35(10):612–23. https://doi.org/10.1093/eurheartj/eht114.

  84. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287–306. https://doi.org/10.1016/j.mayocp.2014.05.013.

  85. Donnellan E, Masri A, Johnston DR, Pettersson GB, Rodriguez LL, Popovic ZB, et al. Long-term outcomes of patients with mediastinal radiation-associated severe aortic stenosis and subsequent surgical aortic valve replacement: a matched cohort study. J Am Heart Assoc. 2017;6(5). https://doi.org/10.1161/JAHA.116.005396.

  86. Wu W, Masri A, Popovic ZB, Smedira NG, Lytle BW, Marwick TH, et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation. 2013;127(14):1476–85. https://doi.org/10.1161/CIRCULATIONAHA.113.001435.

  87. Coronary Revascularization Writing G, Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA, et al. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Thorac Cardiovasc Surg. 2012;143(4):780–803. https://doi.org/10.1016/j.jtcvs.2012.01.061.

  88. Reed GW, Masri A, Griffin BP, Kapadia SR, Ellis SG, Desai MY. Long-term mortality in patients with radiation-associated coronary artery disease treated with percutaneous coronary intervention. Circ Cardiovasc Interv. 2016;9(6). https://doi.org/10.1161/CIRCINTERVENTIONS.115.003483.

  89. Sio TT, Liang JJ, Chang K, Jayakrishnan R, Novotny PJ, Prasad A, et al. Dosimetric correlate of cardiac-specific survival among patients undergoing coronary artery stenting after thoracic radiotherapy for cancer. Am J Clin Oncol. 2017;40(2):133–9. https://doi.org/10.1097/COC.0000000000000135.

  90. Fender EA, Liang JJ, Sio TT, Stulak JM, Lennon RJ, Slusser JP, et al. Percutaneous revascularization in patients treated with thoracic radiation for cancer. Am Heart J. 2017;187:98–103. https://doi.org/10.1016/j.ahj.2017.02.014.

  91. Liang JJ, Sio TT, Slusser JP, Lennon RJ, Miller RC, Sandhu G, et al. Outcomes after percutaneous coronary intervention with stents in patients treated with thoracic external beam radiation for cancer. JACC Cardiovasc Interv. 2014;7(12):1412–20. https://doi.org/10.1016/j.jcin.2014.05.035.

  92. Djarv T, Lagergren J, Blazeby JM, Lagergren P. Long-term health-related quality of life following surgery for oesophageal cancer. Br J Surg. 2008;95(9):1121–6. https://doi.org/10.1002/bjs.6293.

    Article  CAS  PubMed  Google Scholar 

  93. Mc Cormack O, Zaborowski A, King S, Healy L, Daly C, O’Farrell N, et al. New-onset atrial fibrillation post-surgery for esophageal and junctional cancer: incidence, management, and impact on short- and long-term outcomes. Ann Surg. 2014;260(5):772–8; discussion 8. https://doi.org/10.1097/SLA.0000000000000960.

    Article  PubMed  Google Scholar 

  94. Biersmith MA, Tong MS, Guha A, Simonetti OP, Addison D. Multimodality cardiac imaging in the era of emerging cancer therapies. J Am Heart Assoc. 2020;9(2):e013755. https://doi.org/10.1161/JAHA.119.013755.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Institute NC. Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Breast Cancer. 2020. https://seer.cancer.gov/statfacts/html/breast.html. Accessed April 30th 2020.

  96. Lohr F, El-Haddad M, Dobler B, Grau R, Wertz HJ, Kraus-Tiefenbacher U et al. Potential effect of robust and simple IMRT approach for left-sided breast cancer on cardiac mortality. International journal of radiation oncology, biology, physics. 2009;74(1):73–80. https://doi.org/10.1016/j.ijrobp.2008.07.018.

  97. Apter S, Shemesh J, Raanani P, Portnoy O, Thaler M, Zissin R et al. Cardiovascular calcifications after radiation therapy for hodgkin lymphoma: computed tomography detection and clinical correlation. Coronary artery disease. 2006;17(2):145–51.

  98. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. The New England journal of medicine. 2020;382(15):1395–407 https://doi.org/10.1056/NEJMoa1915922.

  99. Yasushi Ueki M, Benjamin Vögeli, BA, Alexios Karagiannis, PHD, Thomas Zanchin, MD, Christian Zanchin, MD, Daniel Rhyner, MD, Tatsuhiko Otsuka, MD, Fabien Praz, MD, George C.M. Siontis, MD, PHD, Christina Moro, RN, Stefan Stortecky, MD, Michael Billinger, MD, Marco Valgimigli, MD, PHD, Thomas Pilgrim, MD, Stephan Windecker, MD, Thomas Suter, MD, Lorenz Räber, MD, PHD. Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention. JACC Cardiology 2019;1(2). https://doi.org/10.1016/j.jaccao.2019.11.001.

Download references

Funding

The authors thank the patients and their families treated at The Ohio State University Comprehensive Cancer Center. This work was supported, in part, by the National Cancer Institutes (NCI) grant P30 CA016058 and by K12CA133250 (DA).

Author information

Author notes

  1. Lisa Kim, Emefah C. Loccoh and Eric D. Miller contributed equally to this work.

Authors and Affiliations

  1. Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH, USA

    Lisa Kim, Reynaldo Sanchez, Patrick Ruz, Uzoma Anaba, Jeremy Slivnick, Ajay Vallakati, Ragavendra Baliga & Daniel Addison

  2. Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

    Emefah C. Loccoh, Terence M. Williams, Ahmet Ayan & Eric D. Miller

  3. Division of Cancer Control and Prevention, James Cancer Hospital and Solove Research Institute at The Ohio State University, Columbus, OH, USA

    Daniel Addison

  4. Division of Cardiology, The Ohio State University Wexner Medical Center, Davis Heart and Lung Research Institute, 473 W. 12th Ave., Columbus, OH, 43210, USA

    Daniel Addison

Authors
  1. Lisa Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emefah C. Loccoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reynaldo Sanchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrick Ruz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Uzoma Anaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Terence M. Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jeremy Slivnick
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ajay Vallakati
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ragavendra Baliga
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ahmet Ayan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Eric D. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Daniel Addison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Addison.

Ethics declarations

Conflict of Interest

All other authors declare no conflicts of interests in relation to the work presented in this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Management of Acute Coronary Syndromes

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, L., Loccoh, E.C., Sanchez, R. et al. Contemporary Understandings of Cardiovascular Disease After Cancer Radiotherapy: a Focus on Ischemic Heart Disease. Curr Cardiol Rep 22, 151 (2020). https://doi.org/10.1007/s11886-020-01380-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-020-01380-4

Keywords

Search

Navigation